Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2014

View Archived Issues

Visual acuity improvement seen in interim results from squalamine eye drops trial

Optimization of a GPR40 agonist for type 2 diabetes

Aurigene and Orion form BET bromodomain collaboration

Nandrolone decanoate/vitamin D3 fixed-dose combination evaluated in multiple doses

Roche and Ferring collaborate on personalized female infertility treatment

Johnson & Johnson and Dana-Farber Cancer Institute establish lung cancer collaboration

DART Therapeutics changes name

Targacept begins phase I/II study of TC-6499 in diabetic gastroparesis

GSK begins phase III study of eltrombopag in myelodysplastic syndromes

Aerie Pharmaceuticals reports phase IIb results for Roclatan

Novel neurogenesis-stimulating agents disclosed by Roche

Roche divulges novel MSP receptor agonists

Bayer patent describes potential hemophilia treatments

BioMarin Pharmaceutical discloses new fusion protein for LSD

Japanese researchers present radiation-induced injury treatments

HerpV vaccine shows significant reduction in viral burden

Coronado Biosciences reports topline results from investigator-initiated pilot study

NovaBiotics begins phase IIa study of Lynovex in cystic fibrosis

Eisai submits first MAA for anticancer agent lenvatinib in Japan

Boehringer Ingelheim's idarucizumab receives FDA breakthrough therapy designation

Basilea initiates phase IIa trial of BAL-101553

Nora Therapeutics begins phase II study of NT-100 in women with recurrent pregnancy loss

Phase II results reported on refametinib in patients with pancreatic cancer

Aurinia initiates phase IIb trial of voclosporin in lupus nephritis

Cancer stemness kinase inhibitor BBI-503 tested in patients with advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...